Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

Chezi Ganzel, Zhuoxin Sun, Larry D. Cripe, Hugo F. Fernandez, Dan Douer, Jacob M. Rowe, Elisabeth M. Paietta, Rhett Ketterling, Michael J. O'Connell, Peter H. Wiernik, John M. Bennett, Mark R. Litzow, Selina M. Luger, Hillard M. Lazarus, Martin S. Tallman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study examines the long-term OS of relapsed AML patients who were enrolled to 9 successive ECOG-ACRIN trials for newly diagnosed AML, during 1984-2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow-up was 9.7 years. The median OS from relapse was 0.5 years and the 5-year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.

Original languageEnglish (US)
Pages (from-to)1074-1081
Number of pages8
JournalAmerican Journal of Hematology
Volume93
Issue number8
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

Survival
Recurrence
Homologous Transplantation
Cytogenetics

ASJC Scopus subject areas

  • Hematology

Cite this

Ganzel, C., Sun, Z., Cripe, L. D., Fernandez, H. F., Douer, D., Rowe, J. M., ... Tallman, M. S. (2018). Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. American Journal of Hematology, 93(8), 1074-1081. https://doi.org/10.1002/ajh.25162

Very poor long-term survival in past and more recent studies for relapsed AML patients : The ECOG-ACRIN experience. / Ganzel, Chezi; Sun, Zhuoxin; Cripe, Larry D.; Fernandez, Hugo F.; Douer, Dan; Rowe, Jacob M.; Paietta, Elisabeth M.; Ketterling, Rhett; O'Connell, Michael J.; Wiernik, Peter H.; Bennett, John M.; Litzow, Mark R.; Luger, Selina M.; Lazarus, Hillard M.; Tallman, Martin S.

In: American Journal of Hematology, Vol. 93, No. 8, 01.08.2018, p. 1074-1081.

Research output: Contribution to journalArticle

Ganzel, C, Sun, Z, Cripe, LD, Fernandez, HF, Douer, D, Rowe, JM, Paietta, EM, Ketterling, R, O'Connell, MJ, Wiernik, PH, Bennett, JM, Litzow, MR, Luger, SM, Lazarus, HM & Tallman, MS 2018, 'Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience', American Journal of Hematology, vol. 93, no. 8, pp. 1074-1081. https://doi.org/10.1002/ajh.25162
Ganzel, Chezi ; Sun, Zhuoxin ; Cripe, Larry D. ; Fernandez, Hugo F. ; Douer, Dan ; Rowe, Jacob M. ; Paietta, Elisabeth M. ; Ketterling, Rhett ; O'Connell, Michael J. ; Wiernik, Peter H. ; Bennett, John M. ; Litzow, Mark R. ; Luger, Selina M. ; Lazarus, Hillard M. ; Tallman, Martin S. / Very poor long-term survival in past and more recent studies for relapsed AML patients : The ECOG-ACRIN experience. In: American Journal of Hematology. 2018 ; Vol. 93, No. 8. pp. 1074-1081.
@article{b05c98458d1c415083ae76a16272f7d4,
title = "Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience",
abstract = "This study examines the long-term OS of relapsed AML patients who were enrolled to 9 successive ECOG-ACRIN trials for newly diagnosed AML, during 1984-2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1{\%}) achieved CR1 and of these, 58.9{\%} relapsed. The median follow-up was 9.7 years. The median OS from relapse was 0.5 years and the 5-year OS was 10 (±1){\%}. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.",
author = "Chezi Ganzel and Zhuoxin Sun and Cripe, {Larry D.} and Fernandez, {Hugo F.} and Dan Douer and Rowe, {Jacob M.} and Paietta, {Elisabeth M.} and Rhett Ketterling and O'Connell, {Michael J.} and Wiernik, {Peter H.} and Bennett, {John M.} and Litzow, {Mark R.} and Luger, {Selina M.} and Lazarus, {Hillard M.} and Tallman, {Martin S.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/ajh.25162",
language = "English (US)",
volume = "93",
pages = "1074--1081",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Very poor long-term survival in past and more recent studies for relapsed AML patients

T2 - The ECOG-ACRIN experience

AU - Ganzel, Chezi

AU - Sun, Zhuoxin

AU - Cripe, Larry D.

AU - Fernandez, Hugo F.

AU - Douer, Dan

AU - Rowe, Jacob M.

AU - Paietta, Elisabeth M.

AU - Ketterling, Rhett

AU - O'Connell, Michael J.

AU - Wiernik, Peter H.

AU - Bennett, John M.

AU - Litzow, Mark R.

AU - Luger, Selina M.

AU - Lazarus, Hillard M.

AU - Tallman, Martin S.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - This study examines the long-term OS of relapsed AML patients who were enrolled to 9 successive ECOG-ACRIN trials for newly diagnosed AML, during 1984-2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow-up was 9.7 years. The median OS from relapse was 0.5 years and the 5-year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.

AB - This study examines the long-term OS of relapsed AML patients who were enrolled to 9 successive ECOG-ACRIN trials for newly diagnosed AML, during 1984-2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow-up was 9.7 years. The median OS from relapse was 0.5 years and the 5-year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.

UR - http://www.scopus.com/inward/record.url?scp=85051729263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051729263&partnerID=8YFLogxK

U2 - 10.1002/ajh.25162

DO - 10.1002/ajh.25162

M3 - Article

AN - SCOPUS:85051729263

VL - 93

SP - 1074

EP - 1081

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -